From MASLD to HCC: What's in the middle?

Area of Science:

• Hepatology
• Oncology
• Immunology

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD) involves triglyceride accumulation in liver cells, leading to damage.
• MASLD can progress to metabolic dysfunction-associated steatohepatitis (MASH), causing inflammation, fibrosis, and cirrhosis.
• These conditions increase the risk of hepatocellular carcinoma (HCC) due to chronic inflammation and immune system alterations.

Purpose of the Study:

• To explore the link between hepatic inflammation and the progression of MASLD to MASH and HCC.
• To understand how inflammation influences the immune landscape in liver cancer.
• To identify therapeutic targets for MASLD and HCC by understanding inflammatory mechanisms.

Main Methods:

• Review of current literature on MASLD, MASH, liver fibrosis, and HCC.
• Analysis of cellular and molecular mechanisms of hepatic inflammation.
• Examination of the role of inflammation in immune surveillance and cancer progression.

Main Results:

• Chronic inflammation is a key driver in MASLD progression and HCC development.
• Inflammation alters the liver's immune microenvironment, potentially leading to immune exhaustion.
• Inflammatory processes contribute to malignant transformation, proliferation, and cancer progression.

Conclusions:

• Understanding hepatic inflammation is crucial for managing MASLD and preventing its progression.
• Targeting inflammatory pathways may offer novel therapeutic strategies for both MASLD and HCC.
• Further research into immune system modulation in liver disease is warranted.